Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Income towards Parent Company (2016 - 2024)

Summit Therapeutics filings provide 11 years of Income towards Parent Company readings, the most recent being -$65.6 million for Q4 2024.

  • Quarterly Income towards Parent Company fell 81.23% to -$65.6 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$65.6 million through Sep 2025, up 68.03% year-over-year, with the annual reading at -$234.7 million for FY2024, 61.84% up from the prior year.
  • Income towards Parent Company hit -$65.6 million in Q4 2024 for Summit Therapeutics, down from -$60.8 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at -$9.0 million in Q1 2020 and bottomed at -$537.2 million in Q1 2023.
  • Average Income towards Parent Company over 5 years is -$53.0 million, with a median of -$20.4 million recorded in 2022.
  • The largest annual shift saw Income towards Parent Company tumbled 2324.2% in 2023 before it soared 91.53% in 2024.
  • Summit Therapeutics' Income towards Parent Company stood at -$13.5 million in 2020, then crashed by 100.13% to -$27.1 million in 2021, then grew by 25.09% to -$20.3 million in 2022, then plummeted by 78.38% to -$36.2 million in 2023, then plummeted by 81.23% to -$65.6 million in 2024.
  • Per Business Quant, the three most recent readings for SMMT's Income towards Parent Company are -$65.6 million (Q4 2024), -$60.8 million (Q3 2024), and -$62.7 million (Q2 2024).